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In vivo metabolic imaging of 
Traumatic Brain Injury
Caroline Guglielmetti1,2, Austin Chou1,3, Karen Krukowski1,3, Chloe Najac2, Xi Feng1,3,  
Lara-Kirstie Riparip1,3, Susanna Rosi1,3,4,5,6 & Myriam M. Chaumeil1,2
Complex alterations in cerebral energetic metabolism arise after traumatic brain injury (TBI). To date, 
methods allowing for metabolic evaluation are highly invasive, limiting our understanding of metabolic 
impairments associated with TBI pathogenesis. We investigated whether 13C MRSI of hyperpolarized 
(HP) [1-13C] pyruvate, a non-invasive metabolic imaging method, could detect metabolic changes in 
controlled cortical injury (CCI) mice (n = 57). Our results show that HP [1-13C] lactate-to-pyruvate ratios 
were increased in the injured cortex at acute (12/24 hours) and sub-acute (7 days) time points after 
injury, in line with decreased pyruvate dehydrogenase (PDH) activity, suggesting impairment of the 
oxidative phosphorylation pathway. We then used the colony-stimulating factor-1 receptor inhibitor 
PLX5622 to deplete brain resident microglia prior to and after CCI, in order to confirm that modulations 
of HP [1-13C] lactate-to-pyruvate ratios were linked to microglial activation. Despite CCI, the HP [1-
13C] lactate-to-pyruvate ratio at the injury cortex of microglia-depleted animals at 7 days post-injury 
remained unchanged compared to contralateral hemisphere, and PDH activity was not affected. 
Altogether, our results demonstrate that HP [1-13C] pyruvate has great potential for in vivo non-invasive 
detection of cerebral metabolism post-TBI, providing a new tool to monitor the effect of therapies 
targeting microglia/macrophages activation after TBI.
Traumatic brain injury (TBI) is a complex and heterogeneous brain pathology characterized by various degrees 
of tissue damage, hemorrhages and edema caused by the primary mechanical insult and subsequent secondary 
injury responses such as neuroinflammation1–6. Importantly, TBI is a major environmental risk factor for the 
development of neurodegenerative diseases with an estimated prevalence of 3.2–5.3 million Americans suffering 
from long-term complications and chronic disabilities3,7.
Impairment in energy metabolism following TBI has been reported to be associated with complex cellu-
lar processes in relation to disturbed ion homeostasis, mitochondrial defects, hypoxia, and inflammation4–6,8,9. 
Monitoring of brain metabolism after injury is of utmost importance, as it would help predict the incidence of 
secondary insults and define subsequent therapeutic strategies to minimize such occurrences10. To date, eval-
uation of cerebral metabolism usually relies on invasive methods, such as microdialysis, for direct assessment 
of brain metabolites or indirect measures of arterio-venous metabolite concentrations11,12. These methods have 
demonstrated that injured tissue is characterized by high lactate level and a high lactate-to-pyruvate ratio13–15. 
Amongst the non-invasive methods available in the clinical setting, proton magnetic resonance spectroscopy 
(1H-MRS) is of high interest as it allows the detection of brain metabolites, including lactate16–18. Several studies 
have shown that elevated lactate concentration in patients following brain injury correlates with poor progno-
sis, cognitive decline and high mortality8,14,19,20. However, because steady-state metabolites levels as detected by 
1H-MRS do not directly reflect alterations in metabolic pathways, the exact mechanisms underlying the observed 
metabolic changes following TBI remain poorly understood and represent a matter of debate8,21.
Over the past decade, hyperpolarized 13C magnetic resonance spectroscopic imaging (HP 13C MRSI) has 
emerged as a clinically translatable neuroimaging method of high potential. This new imaging strategy allows 
monitoring of enzymatic reactions in vivo in real-time after injection of so-called hyperpolarized (HP) 13C-labeled 
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probes22–24. HP 13C MRSI has notably improved the detection of cancerous lesions through the monitoring of 
increased conversion of HP [1-13C] pyruvate to HP [1-13C] lactate under aerobic conditions, the Warburg effect 
characteristic of cancer cells25,26.
Importantly, DeVience et al. have recently shown that HP 13C MRSI can detect altered HP [1-13C] 
pyruvate-to-lactate conversion in a rat model of TBI, at an acute time point (4 hours) following injury27. In an 
effort to assess the potential value of HP 13C MRSI in TBI, we here questioned whether HP 13C MRSI could 
monitor acute, subacute and chronic metabolic changes that occur following TBI. To do so, we performed a 
longitudinal study in mice that received a controlled cortical impact (CCI) and were imaged prior to injury 
(Baseline) and at acute (12 and 24 hours), subacute (7 days) and chronic (28 days) time points. Our results showed 
that HP [1-13C] lactate-to-pyruvate ratios were increased in the injured cortex at 12 hours, 24 hours, and 7 days 
post-injury. At these acute and sub acute time points, we additionally observed a decreased activity of pyruvate 
dehydrogenase (PDH), the enzyme which converts pyruvate into Acetyl-CoA, thus providing a likely mechanism 
for the observed increased HP [1-13C] lactate production.
We then evaluated whether HP 13C MRSI could detect microglia/macrophage activation which we have 
previously shown to contribute to secondary injury responses and cognitive decline following TBI5,28. We used 
the colony-stimulating factor-1 receptor (CSF1R) inhibitor PLX5622 to deplete up to 90% of the microglia in 
the adult mouse brain prior to CCI29. We found that microglia depletion prevented the increase in HP [1-13C] 
lactate-to-pyruvate ratios at 7 days post-injury, and that PDH activity was also unchanged compared to the con-
tralateral hemisphere in PLX5622-treated brains. These results suggest a crucial role for microgliosis in energy 
metabolism changes at subacute time points following injury. Furthermore, our results highlight the potential 
of 13C MRSI of HP [1-13C] pyruvate to non-invasively detect alterations of cerebral metabolism after injury and 
provide a novel tool to monitor the effect of innovative therapies targeting microglia/macrophage activation after 
TBI.
Materials and Methods
Animals and experimental outline. All experiments were conducted in accordance with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional 
Animal Care and Use Committee of the University of California (San Francisco, CA).
Twelve to fifteen weeks old C57/BL6 male mice (n = 57 mice) were purchased from Jackson Laboratories 
and housed under 12:12 light-dark cycle with food and water ad-libitum. For longitudinal MR imaging, a sub-
set of mice (n = 10 CCI; n = 5 Sham) were imaged prior to surgery (Baseline) and at twelve hours (12 hours), 
twenty-four hours (24 hours), seven days (7 days) and twenty-eight days (28 days) post-injury. A separate group 
of mice that did not undergo MR imaging was used for immunofluorescence staining and enzyme activity assays 
(n = 3–8 animals per time point). An additional group of mice (n = 11) received PLX5622 supplemented diet 
(Plexxikon Inc.) for a total period of fourteen days. After 7 days of receiving PLX5622 diet, all mice underwent 
CCI surgery and were kept to recover for an additional period of 7 days. A subset of these mice (n = 5) underwent 
MR imaging one day prior to CCI (Baseline) and 7 days post-injury. At 7 days post-injury, mice were euthanized 
and tissue was collected for immunofluorescence analyses (n = 5) and enzyme activity assays (n = 6). All mice 
were euthanized using a mixture of ketamine (150 mg/kg)/xylazine (15 mg/kg) in accordance with standard ani-
mal protocols. The time line for experiment is illustrated in Supplementary Fig. 1A-B, and the number of animals 
for each experimental group is detailed in Supplementary Tables 1 and 2.
Surgical procedures. Animals were anesthetized and maintained under 2.5% isoflurane in O2 with a non-
rebreathing nose cone and passive exhaust system connected to a stereotaxic frame (David Kopf). Once animals 
were secured with nontraumatic ear bars, eye ointment was applied and their heads were cleared of any hair 
around the scalp. After betadine application, a midline incision was made through the scalp. TBI was reproduced 
in the parietal lobe using the CCI model. Mice received a craniectomy ∼3.5 mm in diameter using an electric 
microdrill with the center point determined by a digitally calibrated manipulator arm (Leica) to the coordi-
nates: anteroposterior, −2.0 mm; mediolateral, 2.0 mm, with respect to bregma. Explicit attention was paid to 
prevent damage to the dura during craniectomy; any animal in which the dura was disrupted, as assessed by 
excessive bleeding, was omitted from the study and replaced by another littermate. After craniectomy, contusion 
was achieved using a 3.0 mm convex tip attached to an electromagnetic impactor (Leica) mounted to the digitally 
calibrated manipulator arm. To impact flush with the natural curvature of the head/tissue, the manipulator arm 
was rotated 20° on the vertical axis. The parameters for impact were for a contusion depth of 0.95 mm (from 
dura), velocity was constant at 4.0 m/s, and the impact was sustained for 300 ms. After CCI injury, the scalp was 
sutured and each animal received 0.5 ml of physiologic saline (i.p.) before being placed in a water-heated incu-
bation chamber (37 °C) until they fully recovered as exhibited by resumption of movement and grooming. Sham 
uninjured animals received the craniectomy as described above but the scalp was sutured withouth impact. All 
animals fully recovered from surgical procedures and exhibited normal weight gain for the duration.
In vivo MR acquisitions. All in vivo MR experiments were conducted on a 14.1 tesla vertical MR system 
(Agilent Technologies, Palo-Alto, CA) equipped with 100 G/cm gradients and a dual tune 1H-13C volume coil 
(ØI = 40 mm) or a single tuned 1H proton coil (ØI = 40 mm). For each imaging session, mice were anesthetized 
using isoflurane (1–2% in O2) and a 27 G catheter was secured in the tail vein to allow for intravenous (iv) injec-
tion of the HP probe. Animals were then positioned in a dedicated craddle maintaining constant anesthesia 
and placed in the MR bore; respiration and temperature were continuously monitored during all acquisitions to 
ensure animal well-being and data reproducibility. First, axial T2-weighted images were acquired for adequate 
positioning of the grid used for HP 13C acquisitions. The following parameters were used: TE/TR = 20/1200 ms, 
slice thickness = 1.8 mm, number of averages = 2, matrix = 256 × 256, field of view (FOV) = 30 × 30 mm². For 
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HP 13C MRSI acquisitions, 24 μL of [1-13C] pyruvate preparation was hyperpolarized using a Hypersense DNP 
polarizer (Oxford Instruments) for one hour30. After dissolution, HP [1-13C] pyruvate was rapidly dissolved in 
isotonic buffer (pH~7) to a final concentration of 80 mM. A final volume of 300 μL of the HP [1-13C] pyruvate 
solution was then injected iv over 12 sec through the tail vein catheter. From the beginning of the iv injection of 
HP [1-13C] pyruvate, 2D dynamic chemical shift imaging (CSI) 13C data were acquired using the following param-
eters: TE/TR = 1.2/60 ms; spectral width = 2500 Hz; 128points; 4 sec temporal resolution; flip angle (FA) = 10 deg; 
FOV = 24 × 24 mm²; 5 mm slice thickness. A representative dataset is shown in Supplementary Fig. 1C. Next, 
axial T2-weighted Fast Spin Echo images were acquired for the evaluation of CCI-induced brain lesions. The 
following parameters were used: TE/TR = 12/2000 ms, echo train = 8, slice thickness = 0.5 mm, number of aver-
ages = 2, matrix = 256 × 256, field of view (FOV) = 30 × 30 mm².
MR data analysis. HP 13C MRSI datasets were analyzed using the in-house SIVIC software (http://source-
forge.net/apps/trac/sivic/) and custom-built programs written in MATLAB (MATLAB R2011b, The MathWorks 
Inc.). The k-space dimensions were zero-filled by a factor of two resulting in a 16 × 16 matrix. Spectra were 
summed over time and a lorentzian shape was used to fit the HP [1-13C] pyruvate and [1-13C] lactate peaks on 
the sum spectrum. Then, area under the curve (AUC) of HP [1-13C] pyruvate and AUC of HP [1-13C] lactate 
lorentzian fits were measured and the HP [1-13C] lactate-to-pyruvate ratio was calculated as the ratio of the AUC. 
Regions of interest including the injured and contralateral hemispheres were defined on T2-weighted images and 
HP [1-13C] lactate-to-pyruvate ratios were compiled, as described by Daniels et al.31, and reported as mean of the 
corresponding voxels for the injured and contralateral hemispheres. Color heatmaps of HP [1-13C] pyruvate, HP 
[1-13C] lactate and HP [1-13C] lactate-to-pyruvate ratio were generated using a linear-based interpolation of the 
13C 2D CSI data to the resolution of the anatomical images using custom-built programs written in MATLAB and 
SIVIC. For anatomical analyses, three regions of interest including the ventricles, the lesioned area and the cavi-
tation were manually delineated on T2-weighted images according to the Franklin and Paxinos anatomical mouse 
brain atlas with AMIRA software (Mercury Computer systems, San Diego, USA), as illustrated in Supplementary 
Fig. 2. Next, the volume of the regions of interest and 3D reconstruction were obtained using AMIRA software.
Immunofluorescence acquisition and analysis. All immunofluorescence analyses were performed 
according to previously described procedures. First, mice were transcardially perfused with ice-cold phosphate 
buffered saline followed by ice-cold 4% paraformaldehyde (PFA). Next, brains were dissected and further fixated 
in 4% PFA for 2 h, then dehydrated through a sucrose gradient (2 hours at 5%, 2 hours at 10% and overnight 
at 20%). Afterwards, brain tissue was snap-frozen in liquid nitrogen and kept at −80 °C until further process-
ing. Ten µm-thick cryosections were collected. Immunofluorescence staining was performed on brain slides 
using the following antibody combinations: a primary rabbit anti-Iba1 antibody (Wako, 019–19741, 1:500 dilu-
tion) with a secondary donkey anti-rabbit Alexa Fluor 555 (Invitrogen, A31572, 1:1000 dilution), a primary rat 
anti-CD68 (BioRad, MCA1957, 1:100 dilution) with a secondary anti-rat AF488 (Life Technologies, A11006, 
1:200) and a primary rat anti-mouse CD11b (AbD Serotec, MCA711G, 1:200) with a secondary anti-rat AF488 
(Life Technologies, A11006, 1:200). Slides were counterstained using Hoechst 33342 (Invitrogen, H3570, 1:2000 
dilution). Following staining, sections were mounted using Prolong Gold Antifade (Invitrogen, P36930). All 
imaging was achieved using a Zeiss Imager.Z1 Apotome microscope controlled by ZEN software (Zeiss 2012). 
Quantitative analyses of immunofluorescence images were performed using NIH ImageJ analysis software 
(v1.46r). The degree of microglia/macrophages (Iba-1) and CD68 and CD11b expression was determined based 
on the image-covering staining and expressed as percentage of the total area, as previously described32.
Spectrophotometric assays. Separate groups of mice underwent CCI surgery and were euthanized and 
transcardially perfused with ice-cold phosphate buffered saline at each time point of interest (Naive, 12 hours, 
24 hours, 7 days and 28 days post-injury). Mice that received the PLX5622 or control diet were euthanized at 7 
days post-injury. Brains were rapidly dissected and the ipsilateral to injury and contralateral cortices were iso-
lated, snap-frozen and stored at −80 °C until further processing. The enzymatic activity of PDH was assessed 
using spectrophotometric activity assay kit (ab109902, Abcam), and the enzymatic activity of lactate dehydroge-
nase (LDH), (Vmax) was assessed as previously shown33. PDH and LDH enzymatic activities were normalized 
to the concentration of protein determined by the Bradford method; results are expressed as percentage of the 
contralateral cortices (n = 4–8 mice per group).
Statistical analysis. Results are expressed as mean ± standard error of the mean (sem). A repeated meas-
ures ANOVA was used to evaluate statistical significance of the T2-weighted MRI. Two-Way ANOVA was used 
to determine statistical significance of HP 13C MRSI between injured and contralateral hemispheres over time. 
Statistical analyses of HP [1-13C] lactate-to-pyruvate ratio, expressed as a percent of the contralateral hemisphere, 
and enzyme activity assays for PDH and LDH were performed using a One-Way ANOVA. For immunofluores-
cence analyses, a t-test was used to evaluate statistical significance between control-treated and PLX5622-treated 
groups. All given p-values were corrected for multiple testing using the Tukey HSD post-hoc test (*p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001).
Results
Longitudinal evaluation of TBI using high field T2-weighted MR imaging. T2-weigthed MR images 
were acquired at high field strength (14.1 Tesla) to detect anatomical alterations following CCI. Mice were imaged 
prior to injury (Baseline), 12 hours, 24 hours, 7 days and 28 days post-injury.
The lesioned area, composed of degenerating edematous tissue and blood, was detected as early as 12 hours 
post-injury and appeared as a mix of hyper-intense and hypo-intense contrast in the cortex of the hemisphere 
that received the CCI (Fig. 1A). Longitudinal T2-weigthed imaging showed that the volume of the lesioned tissue, 
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depicted in red in the representative 3D reconstruction (Fig. 1B), peaks at 12 hours and 24 hours post-injury 
(Fig. 1C, p < 0.0001 at both 12 hours and 24 hours, compared to Baseline), decreases by 53 ± 9% at 7 days 
(p = 0.0003, compared to 24 hours), and persists until 28 days post-injury (p = 0.0005, compared to Baseline). At 
7 days and 28 days post-injury, part of the lesioned tissue is being replaced by a well-defined cavity (p = 0.0174, 
compared to Baseline), most likely filled with cerebral spinal fluid, observed as a bright hyper-intense contrast 
on T2-weighted images (blue in the 3D reconstruction, Fig. 1B). In contrast, the total volume of the ventricles 
remained unchanged over time (p = 0.9292).
Longitudinal MR metabolic imaging following TBI reveals a transient increase of the HP [1-13C] 
lactate-to-pyruvate ratio paralleled by decreased PDH activity. Next, we investigated whether 13C 
MRSI of HP [1-13C] pyruvate can detect metabolic alterations after CCI. To do so, we performed longitudinal 13C 
MRSI measurements prior to injury (Baseline) and at 12 hours, 24 hours, 7 days and 28 days post-injury.
As shown in Fig. 2A, we observed an increase of HP [1-13C] lactate production in the HP 13C MR spectra from 
the injured hemisphere (red) compared to the contralateral hemisphere (blue) at 7 days post-injury. The corre-
sponding heatmaps (Fig. 2B) show that HP [1-13C] pyruvate distributes evenly within the brain while HP [1-13C] 
lactate level is increased at the injured site.
Quantitative analyses presented in Fig. 2C revealed that HP [1-13C] lactate-to-pyruvate ratio was signifi-
cantly different between injured and contralateral hemispheres (Two-Way ANOVA, p < 0.0001 for hemisphere 
effect, p = 0.0259 for time effect, p = 0.0002 for hemisphere and time interaction). Specifically, the HP [1-13C] 
lactate-to-pyruvate ratio of the injured hemisphere was significantly higher compared to the contralateral hem-
isphere at 12 hours (p = 0.0269), 24 hours (p < 0.0001) and 7 days (p < 0.0001) post-injury but not at 28 days 
post-injury (p = 0.5162). Corresponding HP [1-13C] lactate-to-pyruvate ratio heatmaps clearly indicate that 
the highest value of the HP [1-13C] lactate-to-pyruvate ratio was centered on the injury site (Fig. 2D). Next, we 
evaluated the percent increase of the HP [1-13C] lactate-to-pyruvate ratio in the injured hemisphere compared 
to the contralateral hemisphere. As shown in Fig. 2E, the HP [1-13C] lactate-to-pyruvate ratio in the injured 
hemisphere was significantly higher by 23 ± 7% at 12 hours (p = 0.0002), 36 ± 3% at 24 hours (p < 0.0001), 
37 ± 2% at 7 days (p < 0.0001) and 15 ± 4% at 28 days post injury (p = 0.0132) compared to Baseline. As shown 
in Supplementary Fig. 3, the HP [1-13C] lactate-to-pyruvate ratios, expressed as percent change of the contralat-
eral hemisphere, were significantly different between CCI and Sham animals (Two-Way ANOVA, p = 0.0001 for 
group effect, p < 0.0001 for time effect, p = 0.0702 for group and time interaction). Specifically, the HP [1-13C] 
lactate-to-pyruvate ratio of the CCI group was significantly higher compared to the Sham animals at 12 hours 
(p = 0.0456), 24 hours (p = 0.002) and 7 days (p = 0.0103) post-injury but not at 28 days post-injury (p = 0.2861). 
Additionally, whereas HP [1-13C] lactate-to-pyruvate ratios overtime showed a significant increase in the CCI 
group, at 12 hours (p = 0.0004), 24 hours (p < 0.0001) and 7 days (p < 0.0001) compared to Baseline, this ratio 
showed no significant difference at any time points in the Sham group (p ≥ 0.1004).
To further investigate the origin of HP [1-13C] lactate-to-pyruvate ratio alterations following injury, we evalu-
ated the activity of two keys enzymes that control the fate of pyruvate, namely LDH, which converts pyruvate into 
lactate, and PDH which enables the entry of pyruvate into the TCA cycle. As shown in Fig. 2F,G, PDH activity 
was significantly decreased in the injured hemisphere by 30 ± 6% at 24 hours (p = 0.0358) and 35 ± 7% at 7 days 
post-injury (p = 0.0011) while LDH activity between injured and contralateral hemispheres remained unchanged 
after injury at every time points (p > 0.1769).
Figure 1. Longitudinal evaluation of TBI using high field T2-weighted MR imaging. (A) Representative T2-
weigthed MR images were acquired prior to injury (Baseline), twelve hours (12 h), twenty-four hours (24 h), 
seven days (7 d) and twenty-eight days (28 d) post-injury. Cortical alterations of the tissue microstructure can 
be detected as a mix of hypo-intense and hyper-intense contrast in the injured hemisphere as early as 12 h post-
injury, and persist until 28 d post-injury. The formation of a well-defined cavity can be observed at 7 d/28 d post-
injury. (B) Representative 3D reconstruction of the lesioned area (red), cavitation (blue) and ventricles (yellow) 
for each time point. (C) Quantitative analyses revealed highest lesion size at acute time points following injury 
(12 h and 24 h, p < 0.0001, compared to Baseline). The lesioned area decreased by 53 ± 9% at 7 d (p = 0.0003, 
compared to 24 h) and persists until 28 d post-injury (p = 0.0005, compared to Baseline). The formation of a 
cavitation can be observed by 28 days post-injury (p = 0.0174, compared to Baseline). All values are reported as 
mean ± sem (n = 5 mice).
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The HP [1-13C] lactate-to-pyruvate ratio is sensitive to modulation of microglia/macrophages 
status following TBI. Next, our goal was to evaluate whether 13C MRSI of HP [1-13C] pyruvate can detect 
changes associated with the neuroinflammatory processes following injury.
We specifically narrowed down our study to 7 days post-injury as it corresponds to a subacute time point char-
acterized by a high level of pro-inflammatory microglia and macrophages at the lesion site5,34. In order to evaluate 
possible direct and indirect contribution of microglia and macrophages to the increased HP [1-13C] lactate to 
pyruvate production observed after CCI, we used a CSF1R inhibitor (PLX5622) supplemented diet to deplete the 
brain resident microglial population and peripherally derived macrophages29,35.
We first verified that PLX5622 diet depleted microglia/macrophage in the brain at 7 days post-injury. 
Quantitative analyses of immunofluorescence staining presented in Fig. 3A–D showed a reduction of the 
total microglia and macrophages population (Iba-1, 92 ± 7% decrease, p < 0.0001; CD11b, 83 ± 5% decrease, 
p = 0.0001) as well as a reduction of the lysosomal marker CD68 (76 ± 4% decrease, p = 0.0014) at the site of 
injury in mice that received PLX5622 diet compared to mice who received the control diet. In the contralateral 
Figure 2. Longitudinal MR metabolic imaging following TBI reveals a transient increase of the HP [1-13C] 
lactate-to-pyruvate ratio, which is paralleled by decreased PDH activity. (A) Representative T2-weighted image 
with overlaid grid used for the acquisition of HP 13C MRSI, highlighting the voxels containing the injured 
(red) and contralateral (blue) hemispheres. HP 13C spectra for the contralateral hemisphere (blue) and injured 
hemisphere (red) showed increased HP [1-13C] lactate in the injured hemisphere at 7 days post-injury. (B) 
Corresponding heatmaps of HP [1-13C] pyruvate and HP [1-13C] lactate showed even distribution of HP [1-
13C] pyruvate within the brain while HP [1-13C] lactate is increased at the level of the injury. (C) Quantitative 
analyses of the HP [1-13C] lactate-to-pyruvate ratios revealed a significant increase at 12 h, 24 h and 7 d post-
injury between injured and contralateral hemispheres (Two-Way ANOVA, p < 0.0001 for hemisphere effect, 
p = 0.0259 for time effect, p = 0.0002 for hemisphere and time interaction). (D) Representative heatmaps 
indicating the highest level of the HP [1-13C] lactate-to-pyruvate ratio at the site of injury. (E) HP [1-13C] 
lactate-to-pyruvate ratio expressed as a percent change of the contralateral hemisphere showed increased 
ratios by 23 ± 7% at 12 hours (p = 0.0002), 36 ± 3% at 24 hours (p < 0.0001), 37 ± 2% at 7 days (p < 0.0001) and 
15 ± 4% at 28 days post injury (p = 0.0132) compared to Baseline. (F) PDH activity was significantly decreased 
in the injured hemisphere by 30 ± 6% at 24 h (p = 0.0358) and 35 ± 7% at 7 d post-injury (p = 0.0011) while 
LDH activity remained unchanged (G). All values are reported as mean ± sem (n = 10 mice for HP [1-13C] 
MRSI, n = 4–8 mice per time point for PDH and LDH activity).
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hemisphere, Fig. 3A and Fig. 3E–G, we observed a similar decrease in the population of microglia and mac-
rophages (Iba-1, 84 ± 7% decrease, p = 0.0082; CD11b, 87 ± 6% decrease, p = 0.0019) while CD68 levels were 
below detection. Similar results were obtained in the hilar region of the hippocampus (Supplementary Fig. 4).
Figure 3. Immunofluorescence analyses following TBI and PLX5622 treatment. (A) Representative 
immunofluorescence images taken at 7 d post-injury showing a strong reduction of microglia/macrophages 
(Iba-1, red; CD11b, green), and CD68 expressing microglia/macrophages (yellow) in the group that received the 
PLX5622 compared to control diet. Quantitative analyses in the injured cortex confirmed decrease of  
(B) Iba-1 expressing microglia/macrophage population (92 ± 7%, p < 0.0001), (C) CD11b expressing microglia/
macrophages (83 ± 5%, p = 0.0001), (D) the lysosomal marker CD68 (76 ± 4%, p = 0.0014), in the group 
that received the PLX5622 diet. Similarly, quantitative analyses in the contralateral cortex showed decrease 
of (E) Iba-1 and (F) CD11b expressing microglia/macrophage population (84 ± 7%, p < 0.0082 and 87 ± 6%, 
p < 0.0019, respectively) for mice that received PLX5622 compared to control diet, while the (G) lysosomal 
marker CD68 levels were below detection. All values are reported as mean ± sem (n = 3–5 mice per group).
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7SCIeNTIFIC RepoRTs | 7: 17525  | DOI:10.1038/s41598-017-17758-4
We then investigated whether T2-weighted MRI and 13C MRSI of HP [1-13C] pyruvate would be able to 
detect changes associated with the depletion of microglia/macrophages in mice that received the PLX5622 diet. 
T2-weighted MRI revealed the presence of a lesion and a cavitation in all microglia depleted animals 7 days after 
injury (Supplementary Fig. 5). As shown in Fig. 4A–C, a significant difference in the production of HP [1-13C] 
lactate can be observed between PLX5622 and control-treated mice (Figs 2 and 4A–C). Quantitative analyses con-
firmed that the HP [1-13C] lactate-to-pyruvate ratio at 7 days post-injury was not significantly different between 
injured and contralateral hemispheres in animals that received PLX6522 diet (Two-Way ANOVA, p = 0.089 
for hemisphere effect, p = 0.1804 for time effect, p = 0.2792 for hemisphere and time interaction, Fig. 4B), con-
trasting with the increase of HP [1-13C] lactate-to-pyruvate ratio observed in mice that received a control diet 
(p = 0.0001 at 7 days post-injury, Figs 2C and 4B). Furthermore, as shown in Fig. 4C, no significant changes in 
the HP [1-13C] lactate-to-pyruvate ratio, expressed as percent increase of the contralateral hemisphere, could be 
detected between Baseline and 7 days following PLX5622 diet (p = 0.2138), contrasting with the 37 ± 2% at 7 days 
(p < 0.0001) in control-treated mice (Figs 2E and 4C).
In line with these findings, we did not detect a decrease in PDH activity in the injured hemisphere of mice that 
received a PLX5622 diet (p = 0.9429, Fig. 4D). LDH activity remained unchanged between injured and contralat-
eral hemispheres for all groups (p = 0.1769, Fig. 4E).
Discussion
In this study, we evaluated for the first time the potential of an innovative neuroimaging method, HP 13C MRSI, 
to monitor longitudinal changes in energetic metabolism in a CCI mouse model of TBI. We were able to report 
a significant increase in HP [1-13C] lactate-to-pyruvate ratio at acute and subacute time points following injury, 
Figure 4. The HP [1-13C] lactate-to-pyruvate ratio is sensitive to modulation of microglia/macrophages status 
following TBI. (A) Representative heatmaps of the HP [1-13C] lactate-to-pyruvate ratios and corresponding 
HP 13C spectra showing increased HP [1-13C] lactate-to-pyruvate ratio and increased HP [1-13C] lactate 
production at 7d post-injury in the mouse that received the control diet but not in the mouse that received the 
PLX5622 diet. (B) Quantitative analyses of the HP [1-13C] lactate-to-pyruvate ratios revealed no significant 
differences between the injured and contralateral hemispheres of microglia depleted mice (Two-Way ANOVA, 
p = 0.089 for hemisphere effect, p = 0.1804 for time effect, p = 0.2792 for hemisphere and time interaction) at 
7 days post-injury, contrasting with the increase of HP [1-13C] lactate-to-pyruvate ratio observed in mice that 
received the control diet (p = 0.0001). (C) HP [1-13C] lactate-to-pyruvate ratio, expressed as a percent change 
of the contralateral hemisphere, showed no change of the HP [1-13C] lactate-to-pyruvate ratio at 7 d post-injury 
compared to Baseline in mice that received the PLX5622, in contrast with the 37 ± 2% at 7 d (p < 0.0001) in 
mice that received the control diet. (D) PDH activity was decreased in the injured hemisphere of mice that 
received a control diet (p = 0.0011) but not in mice that received PLX5622 diet (p = 0.9429). (E) LDH activity 
remained unchanged (p = 0.1769). All values are reported as mean ± sem (n = 5–10 mice per group).
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which was associated with a decrease of PDH activity in the injured cortex. We further demonstrated that micro-
glial depletion prior to CCI prevented the injury-induced increase of the HP [1-13C] lactate-to-pyruvate ratio at 
7 days post-injury.
The present results are the first to use HP 13C MRSI to study the longitudinal modulations of the HP [1-13C] 
pyruvate-to-lactate conversion in the mouse brain after focal contusion injury. While DeVience et al. have pre-
viously demonstrated that HP 13C MRSI can detect acute metabolic alterations in a rat model of CCI27, numer-
ous differences can be noted with the current study. Our study expands findings by investigating subacute and 
chronic end points following TBI. At acute time points, computed tomography (CT) is the method of choice 
because of its accessibility, speed of acquisition and accuracy in detecting skull fractures and intracranial hem-
orrhages that require urgent surgical intervention36,37. DeVience et al. used a lower field strength (3 tesla) with a 
single time point acquisition scheme (acquisition of a single spectra at 30 seconds post-injection of HP [1-13C] 
pyruvate), while we evaluated the dynamic conversion of HP [1-13C] pyruvate into lactate by acquiring a series of 
spectra every 3 seconds for a period of a minute. While our experimental design provides an intrinsically lower 
signal-to-noise-ratio of metabolites (due to higher field strength and smaller brain size of mouse versus rat), our 
dynamic acquisition scheme provides a more accurate evaluation of HP [1-13C] pyruvate-to-lactate dynamics and 
subsequent ratios values, which are not sensitive to user-induced experimental variations31.
Elevated lactate levels after TBI have been previously detected using 1H-MRS both in preclinical and clinical 
studies8,17,20. Because 1H MRS provides a measure of the steady-state levels of metabolites (intracellular + extra-
cellular), increased lactate levels, as detected by this method, are often a combination of: 1)modulated intracellu-
lar lactate production through changes in enzyme activities, 2) accumulation of extracellular lactate originating 
from necrotic tissue, and/or 3) reduced lactate clearance rate. In contrast, the HP [1-13C] lactate-to-pyruvate 
ratios as measured by HP 13C MRSI reflect isotopic exchange from HP [1-13C] pyruvate to HP [1-13C] lactate 
through LDH, and are thus a combined indicator of the activity of enzymes that control the fate of pyruvate, and 
intracellular lactate pool-size27,38, as reviewed by Daniels et al.31. Before HP 13C MRSI, in vivo measurements of 
lactate-to-pyruvate ratios were previously accessible only by invasive procedures such as cerebral microdialysis11. 
In contrast to HP 13C MRSI which provide a readout of both enzymatic activity and intracellular lactate levels, 
microdialysis provides measurement of extracellular steady-state lactate-to-pyruvate ratios. It is well-established 
that extracellular lactate increase significantly following TBI and is associated with poor neurological outcome8, 
but whether or not prognosis is correlated with intracellular lactate is unknown. Hyperpolarized 13C MRSI and 
microdialysis thus appear as complementary strategies likely to provide distinct metabolic information. Future 
studies combining hyperpolarized 13C MRSI with microdialysis could be of interest as they would provide a more 
integrated picture of the cerebral metabolic state after injury.
Current neuroimaging methods used for the evaluation of TBI enable the detection of global anatomical 
alterations such as cavitation, hemorrhages, micro bleeds, hematomas, edema, grey and white matter shears, 
and diffuse axonal injury36,37. In our study, we observed discrepancies between anatomical alterations, par-
ticularly lesion size as detected by T2-weighted imaging, and HP [1-13C] lactate-to-pyruvate ratios. At 12 and 
24 hours post-injury, despite similar lesion size, we observed a twenty-three percent increase in the HP [1-13C] 
lactate-to-pyruvate between the two time points. Similarly, the HP [1-13C] lactate-to-pyruvate ratios at 7 
days were comparable to 24 hours post-injury, although there was a forty-six percent decrease in lesion size. 
Altogether, these results highlight the fact that anatomical and metabolic changes provide distinct information 
on the dynamic evolution of the injured tissue following TBI.
LDH is the enzyme that converts pyruvate into lactate and is overexpressed in most cancers25,26, and PDH is 
the enzymatic complex that controls the entrance of pyruvate into the TCA cycle. We therefore studied LDH and 
PDH levels at the same time points at which we measured metabolic changes. Unlike in cancer, no alterations 
of LDH activity were detected at any time points following injury. In contrast, we observed alterations of PDH 
activity following TBI, which likely reflect impairment of the oxidative properties of mitochondria previously 
observed9. Such decrease in PDH activity prevents pyruvate from entering the TCA cycle, which should subse-
quently result in an increased flux of HP [1-13C] pyruvate towards lactate production. In line with these reports, 
we measured a decreased PDH activity at 24 hours and 7 days post injury and demonstrated that these time points 
correspond to the highest HP [1-13C] lactate-to-pyruvate ratio values. Interestingly, at 12 hours post-injury, the 
measured HP [1-13C] lactate-to-pyruvate ratio was variable between individuals. At this time point, PDH activity 
in the injured cortex was not significantly lower than in the contralateral cortex, but displayed a trend toward 
decreased activity compared to Naïve animals. At 28 days post-injury, the HP [1-13C] lactate-to-pyruvate ratio 
were strongly decreased compared to 7 days post-injury (Fig. 2C) and PDH activity is no longer significantly 
different between injured and contralateral cortices.
Besides the initial mechanical insult caused to the brain at the time of injury, the secondary inflammatory 
responses that persist for days to weeks after injury can contribute to the neurological deficits observed after TBI. 
Interestingly, recent studies including these from our group, have shown that modulation of neuroinflamma-
tion following injury ameliorates long-term deficits and as such may represent a valuable tool for prevention of 
neurological disorders associated with TBI1,3,34,39. Elevated numbers of activated microglia and macrophages are 
present in the injured region following trauma, particularly within 3 days to 7 days post-injury4,6. Imaging studies 
using positron emission tomography (PET) and the translocator protein (TSPO) marker for neuroinflammation 
showed the highest levels of TSPO at 6 days post-injury40, in agreement with our findings of highest levels of HP 
[1-13C] lactate-to-pyruvate ratios at 7 days post-injury (Fig. 2C).
It is well-established that upon activation towards a pro-inflammatory phenotype, microglia and macrophages 
undergo metabolic reprogramming41,42 that results in increased glycolysis, lactate production, and inhibition 
PDH activity43,44. Consequently, the presence of pro-inflammatory microglia and macrophages may contribute to 
the observed increase of HP [1-13C] lactate-to-pyruvate ratios. In order to evaluate more selectively the metabolic 
changes associated with TBI-induced activation of microglia and macrophages, we used the CSF1R inhibitor 
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PLX5622 to deplete the microglial and macrophage populations prior to and following CCI. In microglia depleted 
animals, we found that HP [1-13C] lactate-to-pyruvate ratios did not significantly increase in the injured hem-
isphere after TBI as compared to the contralateral hemisphere and that neither PDH nor LDH activity were 
significantly different between hemispheres. These results suggest a crucial role of microglia/macrophages in the 
elevated HP [1-13C] pyruvate-to-lactate conversion at 7 days post-injury. Such changes can reflect a lower number 
of pro-inflammatory microglia at the lesion site, as well as energy metabolism alterations of the injured tissue as 
a whole, as a consequence of altered immune environment. Notably, in this study, we used PLX5622 treatment 
solely as a tool to deplete microglia at the time of injury, in order to determine the specificity of the HP [1-13C] 
lactate-to-pyruvate signal. However, given the role of microglia in the initiation of the inflammatory response 
post-TBI34,45, it is conceivable to consider the therapeutic potential of PLX5622. A limitation to its therapeutic 
use is due to the fact that the initial inflammatory response after CCI takes place in the first 24-48 hours34,45 and 
PLX5622 takes 3–5 days to fully deplete microglia following CCI30,35. Furthermore, our study shows that the 
microglia depleted animals had a bigger lesion compared to control treated animals at 7 days post-injury, thus 
questioning a beneficial role of microglia at the time of injury (Supplementary Fig. 5). At this time, it is thus not 
clear if PLX5622 could have therapeutic potential for TBI, and more studies are needed.
In conclusion, our studies show that metabolic imaging using 13C MRSI of HP [1-13C] pyruvate can probe 
acute and subacute energetic disturbances following TBI. Importantly, we report that elevated HP [1-13C] 
lactate-to-pyruvate ratios at subacute time points are associated with the increased presence of microglia and 
macrophages. Altogether, these findings demonstrate that HP 13C MRSI has potential to enhance the diagnosis 
and monitoring of energetic imbalance following TBI and could serve a novel tool to examine altered immune 
response in other neurological disorders.
References
 1. Kumar, A. & Loane, D. J. Neuroinflammation after traumatic brain injury: opportunities for therapeutic intervention. Brain Behav 
Immun 26, 1191–1201, https://doi.org/10.1016/j.bbi.2012.06.008 (2012).
 2. Masel, B. E. & DeWitt, D. S. Traumatic brain injury: a disease process, not an event. J Neurotrauma 27, 1529–1540, https://doi.
org/10.1089/neu.2010.1358 (2010).
 3. Lozano, D. et al. Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and therapeutic 
opportunities. Neuropsychiatr Dis Treat 11, 97–106, https://doi.org/10.2147/NDT.S65815 (2015).
 4. Simon, D. W. et al. The far-reaching scope of neuroinflammation after traumatic brain injury. Nat Rev Neurol 13, 171–191, https://
doi.org/10.1038/nrneurol.2017.13 (2017).
 5. Morganti, J. M. et al. Age exacerbates the CCR2/5-mediated neuroinflammatory response to traumatic brain injury. J 
Neuroinflammation 13, 80, https://doi.org/10.1186/s12974-016-0547-1 (2016).
 6. Morganti, J. M., Riparip, L. K. & Rosi, S. Call Off the Dog(ma): M1/M2 Polarization Is Concurrent following Traumatic Brain Injury. 
PLoS One 11, e0148001, https://doi.org/10.1371/journal.pone.0148001 (2016).
 7. Zaloshnja, E., Miller, T., Langlois, J. A. & Selassie, A. W. Prevalence of long-term disability from traumatic brain injury in the civilian 
population of the United States, 2005. J Head Trauma Rehabil 23, 394–400, https://doi.org/10.1097/01.HTR.0000341435.52004.ac 
(2008).
 8. Carpenter, K. L., Jalloh, I. & Hutchinson, P. J. Glycolysis and the significance of lactate in traumatic brain injury. Front Neurosci 9, 
112, https://doi.org/10.3389/fnins.2015.00112 (2015).
 9. Opii, W. O. et al. Proteomic identification of oxidized mitochondrial proteins following experimental traumatic brain injury. J 
Neurotrauma 24, 772–789, https://doi.org/10.1089/neu.2006.0229 (2007).
 10. Tisdall, M. M. & Smith, M. Multimodal monitoring in traumatic brain injury: current status and future directions. Br J Anaesth 99, 
61–67, https://doi.org/10.1093/bja/aem143 (2007).
 11. Gallagher, C. N. et al. The human brain utilizes lactate via the tricarboxylic acid cycle: a 13C-labelled microdialysis and high-
resolution nuclear magnetic resonance study. Brain 132, 2839–2849, https://doi.org/10.1093/brain/awp202 (2009).
 12. Jalloh, I. et al. Lactate uptake by the injured human brain: evidence from an arteriovenous gradient and cerebral microdialysis study. 
J Neurotrauma 30, 2031–2037, https://doi.org/10.1089/neu.2013.2947 (2013).
 13. Lama, S. et al. Lactate storm marks cerebral metabolism following brain trauma. J Biol Chem 289, 20200–20208, https://doi.
org/10.1074/jbc.M114.570978 (2014).
 14. Timofeev, I. et al. Cerebral extracellular chemistry and outcome following traumatic brain injury: a microdialysis study of 223 
patients. Brain 134, 484–494, https://doi.org/10.1093/brain/awq353 (2011).
 15. Carpenter, K. L. et al. (13)C-labelled microdialysis studies of cerebral metabolism in TBI patients. Eur J Pharm Sci 57, 87–97, https://
doi.org/10.1016/j.ejps.2013.12.012 (2014).
 16. Schuhmann, M. U. et al. Metabolic changes in the vicinity of brain contusions: a proton magnetic resonance spectroscopy and 
histology study. J Neurotrauma 20, 725–743, https://doi.org/10.1089/089771503767869962 (2003).
 17. Hillary, F. G. et al. Examining lactate in severe TBI using proton magnetic resonance spectroscopy. Brain Inj 21, 981–991, https://
doi.org/10.1080/02699050701426964 (2007).
 18. Marino, S. et al. Acute metabolic brain changes following traumatic brain injury and their relevance to clinical severity and outcome. 
J Neurol Neurosurg Psychiatry 78, 501–507, https://doi.org/10.1136/jnnp.2006.099796 (2007).
 19. Sala, N. et al. Cerebral extracellular lactate increase is predominantly nonischemic in patients with severe traumatic brain injury. J 
Cereb Blood Flow Metab 33, 1815–1822, https://doi.org/10.1038/jcbfm.2013.142 (2013).
 20. Makoroff, K. L., Cecil, K. M., Care, M. & Ball, W. S. Jr. Elevated lactate as an early marker of brain injury in inflicted traumatic brain 
injury. Pediatr Radiol 35, 668–676, https://doi.org/10.1007/s00247-005-1441-7 (2005).
 21. Dienel, G. A. Lactate shuttling and lactate use as fuel after traumatic brain injury: metabolic considerations. J Cereb Blood Flow 
Metab 34, 1736–1748, https://doi.org/10.1038/jcbfm.2014.153 (2014).
 22. Chaumeil, M. M., Najac, C. & Ronen, S. M. Studies of Metabolism Using (13)C MRS of Hyperpolarized Probes. Methods Enzymol 
561, 1–71, https://doi.org/10.1016/bs.mie.2015.04.001 (2015).
 23. Ardenkjaer-Larsen, J. H. et al. Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR. Proceedings of the National 
Academy of Sciences of the United States of America 100, 10158–10163, https://doi.org/10.1073/pnas.1733835100 (2003).
 24. Guglielmetti, C. et al. Hyperpolarized 13C MR metabolic imaging can detect neuroinflammation in vivo in a multiple sclerosis 
murine model. Proc Natl Acad Sci USA 114(33), E6982-E6991, doi:10.1073/pnas.1613345114 (2017).
 25. Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell 
proliferation. Science 324, 1029–1033, https://doi.org/10.1126/science.1160809 (2009).
 26. Nelson, S. J. et al. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-(1)(3)C]pyruvate. Sci Transl Med 5, 
198ra108, https://doi.org/10.1126/scitranslmed.3006070 (2013).
www.nature.com/scientificreports/
1 0SCIeNTIFIC RepoRTs | 7: 17525  | DOI:10.1038/s41598-017-17758-4
 27. DeVience, S. J. et al. Metabolic imaging of energy metabolism in traumatic brain injury using hyperpolarized [1-13C]pyruvate. Sci 
Rep 7, 1907, https://doi.org/10.1038/s41598-017-01736-x (2017).
 28. Chou, A. et al. Inhibition of the integrated stress response reverses cognitive deficits after traumatic brain injury. Proc Natl Acad Sci 
USA, https://doi.org/10.1073/pnas.1707661114 (2017).
 29. Elmore, M. R. et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia 
progenitor cell in the adult brain. Neuron 82, 380–397, https://doi.org/10.1016/j.neuron.2014.02.040 (2014).
 30. Kurhanewicz, J. et al. Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. 
Neoplasia 13, 81–97 (2011).
 31. Daniels, C. J. et al. A comparison of quantitative methods for clinical imaging with hyperpolarized (13)C-pyruvate. NMR in 
biomedicine 29, 387–399, https://doi.org/10.1002/nbm.3468 (2016).
 32. Guglielmetti, C. et al. Diffusion kurtosis imaging probes cortical alterations and white matter pathology following cuprizone 
induced demyelination and spontaneous remyelination. Neuroimage  125,  363–377, https://doi.org/10.1016/j.
neuroimage.2015.10.052 (2016).
 33. Ward, C. S. et al. Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using 
hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res 70, 1296–1305, https://doi.org/10.1158/0008-5472.CAN-09-2251 
(2010).
 34. Morganti, J. M. et al. CCR2 antagonism alters brain macrophage polarization and ameliorates cognitive dysfunction induced by 
traumatic brain injury. The Journal of neuroscience: the official journal of the Society for Neuroscience 35, 748–760, https://doi.
org/10.1523/JNEUROSCI.2405-14.2015 (2015).
 35. Feng, X. et al. Colony-stimulating factor 1 receptor blockade prevents fractionated whole-brain irradiation-induced memory 
deficits. J Neuroinflammation 13, 215, https://doi.org/10.1186/s12974-016-0671-y (2016).
 36. Le, T. H. & Gean, A. D. Neuroimaging of traumatic brain injury. Mt Sinai J Med 76, 145–162, https://doi.org/10.1002/msj.20102 
(2009).
 37. Edlow, B. L. & Wu, O. Advanced neuroimaging in traumatic brain injury. Semin Neurol 32, 374–400, https://doi.
org/10.1055/s-0032-1331810 (2012).
 38. Kettunen, M. I. et al. Magnetization transfer measurements of exchange between hyperpolarized [1-13C]pyruvate and [1-13C]
lactate in a murine lymphoma. Magn Reson Med 63, 872–880, https://doi.org/10.1002/mrm.22276 (2010).
 39. Hanrahan, F. & Campbell, M. In Translational Research in Traumatic Brain Injury Frontiers in Neuroscience (eds D. Laskowitz & G. 
Grant) (2016).
 40. Vallez Garcia, D., Otte, A., Dierckx, R. A. & Doorduin, J. Three Month Follow-Up of Rat Mild Traumatic Brain Injury: A Combined 
[18F]FDG and [11C]PK11195 Positron Emission Study. J Neurotrauma 33, 1855–1865, https://doi.org/10.1089/neu.2015.4230 (2016).
 41. Galvan-Pena, S. & O’Neill, L. A. Metabolic reprograming in macrophage polarization. Frontiers in immunology 5, 420, https://doi.
org/10.3389/fimmu.2014.00420 (2014).
 42. Orihuela, R., McPherson, C. A. & Harry, G. J. Microglial M1/M2 polarization and metabolic states. Br J Pharmacol 173, 649–665, 
https://doi.org/10.1111/bph.13139 (2016).
 43. Jha, M. K. et al. Metabolic Connection of Inflammatory Pain: Pivotal Role of a Pyruvate Dehydrogenase Kinase-Pyruvate 
Dehydrogenase-Lactic Acid Axis. J Neurosci 35, 14353–14369, https://doi.org/10.1523/JNEUROSCI.1910-15.2015 (2015).
 44. Tan, Z. et al. Pyruvate Dehydrogenase Kinase 1 Participates in Macrophage Polarization via Regulating Glucose Metabolism. Journal 
of immunology 194, 6082–6089, https://doi.org/10.4049/jimmunol.1402469 (2015).
 45. Loane, D. J. & Kumar, A. Microglia in the TBI brain: The good, the bad, and the dysregulated. Exp Neurol 275(Pt 3), 316–327, https://
doi.org/10.1016/j.expneurol.2015.08.018 (2016).
Acknowledgements
This work was supported by research grants: NIH/NINDS R21NS096718, NIH/NINDS R01NS102156, Cal-
BRAIN349087, NIH Hyperpolarized MRI Technology Resource Center #P41EB013598, fellowship from the 
NMSS (FG-1507-05297), NIH/NCI R01CA172845, NIH/NCI R01CA1972254, ABTA BRF1700006.
Author Contributions
M.M.C., and S.R. designed research; C.G., A.C., and K.K. performed research; C.N., X.F., and L-K.R., contributed 
new reagents/analytic tools; C.G., and M.M.C. analyzed data; C.G., S.R. and M.M.C. wrote the paper.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-17758-4.
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
